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Abstract
Background: Oral anticoagulation monitoring has traditionally taken place in secondary care
because of the need for a laboratory blood test, the international normalised ratio (INR). The
development of reliable near patient testing (NPT) systems for INR estimation has facilitated
devolution of testing to primary care. Patient self-management is a logical progression from the
primary care model. This study will be the first to randomise non-selected patients in primary care,
to either self-management or standard care.
Method: The study was a multi-centred randomised controlled trial with patients from 49 general
practices recruited. Those suitable for inclusion were aged 18 or over, with a long term indication
for oral anticoagulation, who had taken warfarin for at least six months. Patients randomised to the
intervention arm attended at least two training sessions which were practice-based, 1 week apart.
Each patient was assessed on their capability to undertake self management. If considered capable,
they were given a near patient INR testing monitor, test strips and quality control material for
home testing. Patients managed their own anticoagulation for a period of 12 months and performed
their INR test every 2 weeks. Control patients continued with their pre-study care either attending
hospital or practice based anticoagulant clinics.
Discussion: The methodology used in this trial will overcome concerns from previous trials of
selection bias and relevance to the UK health service. The study will give a clearer understanding
of the benefits of self-management in terms of clinical and cost effectiveness and patient preference.
Introduction
Increasing numbers of patients are receiving anticoagula-
tion therapy, primarily driven by increased indications for
warfarin therapy, particularly for non rheumatic atrial
fibrillation.[1] Oral anticoagulation monitoring has tradi-
tionally taken place in secondary care because of the need
for a laboratory blood test, the International Normalised
Ratio (INR).[2] The INR measures the level of the induced
clotting defect and there is good evidence that the inci-
dence of adverse events is directly related to the intensity
of treatment, with thrombotic events increasing exponen-
tially as the INR decreases below a value of 2.0 and haem-
orrhagic events increasing exponentially as the INR
increases above a value of 4.5.[3]
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receiving warfarin has meant that traditional hospital
based clinics are increasingly unable to cope with the
throughput of patients.[4] This has led to the investiga-
tion of alternative models of care for anticoagulation
management, in particular primary care management
using Near Patient Testing (NPT) devices for INR estima-
tion.[5] Near patient testing can be defined as the per-
formance of a diagnostic test, usually performed in a
hospital pathology laboratory outside the usual setting.
The development of reliable NPT for INR estimation has
facilitated devolution of testing to general practice.[6]
NPT machines for INR estimation have now been subject
to rigorous evaluation in the hospital laboratory and pri-
mary care settings.[7–10]
The Birmingham model of primary care anticoagulation
monitoring[4] (developed by the study investigators)
using NPT and computerised decision support software
(CDSS) was created as a result of this progress and the effi-
cacy, safety and efficiency of the model has been accepted
as a credible alternative to hospital based care.[11]
A further advance for anticoagulation services is the inves-
tigation of patients' ability to manage their own therapeu-
tic monitoring. Patient self-management (PSM) of INR is
a logical progression from the NPT primary care anticoag-
ulation model. PSM offers increased patient empower-
ment to control therapy with a model analogous to home
glucose monitoring using a portable glucometer.[12] It is
essential, however, that the INR can be reliably measured
within home settings, and also that patients are able to
interpret the INR result and alter therapy as appropriate.
We have previously demonstrated in a pilot study involv-
ing 49 patients from 6 general practices that PSM is feasi-
ble within the UK, with PSM patients achieving
satisfactory levels of therapeutic control (74% of time
spent in range compared to 77% in routinely managed
patients).[13,14]
Earlier studies, predominantly from Germany and the
USA have addressed the feasibility of allowing orally anti-
coagulated patients to undertake self-manage-
ment.[12,15–21] (Table 1). These studies offer some
observational evidence to suggest that PSM is a relevant
model of care for long term anticoagulation management
in terms of reliability, convenience and reduced risks. Also
treatment quality is comparable or even better than con-
ventional management.
The studies, however, used highly selected populations
and suffered methodological weaknesses since patients
were usually not randomly selected. Patients selected for
self-management within these studies were inherently
more likely to have better therapeutic control as eligibility
would include levels of 'intelligence', manual dexterity
and previously stable control. Furthermore, these eligibil-
ity criteria were applied subjectively, with no objective
measures of compliance or cognitive ability stated.
The health economic analyses from Germany are further-
more not relevant to the NHS as patient self-management
is 100% reimbursed (subject to satisfactory completion of
a training programme) through private health insurance.
Cost-effectiveness of PSM within the NHS will be sensitive
to the reduction in patient contact with medical services
afforded by the model balanced against the increased cap-
ital costs associated with providing patients with their
own NPT and reagents, and ultimately the incidence of
serious adverse events, particularly stroke.
Major haemorrhagic or thrombotic complications from
warfarin therapy are relatively rare (haemorrhagic 1–3 per
100 patient years and thrombotic 4–6 per 100 patient
years [22,23]) so it is unlikely that a significant difference
between the groups will be shown in this study. The main
implication of the German studies is that self-manage-
ment required only a modest amount of dexterity and
skills. However it is recognised that practical training and
Table 1: 
Study author Country Nature of study Patient Numbers intervention/control Results intervention v control
White et al [12] USA RCT 23/23 93% v 75% *
Sawicki [15] Germany RCT 90/89 53% v 34% **
Hasenkam et al [16] Denmark Matched 21/20 77% v 55% *
Ansell et al [17] USA Matched 20/20 89% v 68% *
Anderson et al [18] Canada Observational 40/self-control 74% ***
Barnado [19] Germany Observational 216/No control 83.1% ***
Massicotte et al [20] Canada Observational 23/No control 63% ***
Korfer and Kortke[21] Germany RCT 279/303 80% v 54% ***
• % time in range, **% patients in range, ***% tests in rangePage 2 of 7
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the success of the self-management programme.
It can be concluded from the published studies that while
self-management appears a credible alternative to existing
models of care, there are currently no data from the UK to
support its use. There are no clinical outcome data in any
of the published studies to support its use either. Evidence
is required from UK trials regarding both clinical and cost-
effectiveness before it can be introduced in the UK on a
wide scale.
The main criticism of studies published thus far is that
standard care within them was poor in comparison to
published UK data.[15,24,25]. This means that any
improvement in therapeutic control and reduction in seri-
ous adverse events associated with self-management will
be exaggerated in comparison to UK models of care.
Therefore, based on the success of observational studies to
date, this study was the first to randomise non-selected
patients in primary care, to receive either PSM or standard
care.
The current study aims to evaluate the clinical and cost-
effectiveness of PSM. It is currently accepted practice that
adequate clinical performance is represented by a level of
60% spent within the therapeutic range.[26]
The intervention, in terms of patient education and PSM,
was therefore be accurately evaluated against standard
care. Standard care being the patients' previous manage-
ment, either attending a hospital or general practice based
anticoagulation clinic. Based upon pre study data col-
lected for this study, frequency of testing on average for
patients participating in standard care is 10 INR tests per
year. There are various models involving a wide range of
health professionals. Patients either attended;
• Hospital based clinics using both venous samples with
laboratory testing or NPT systems.
• Primary care based clinics with three models of care
including
• Phlebotomy only, samples are sent to the hospital lab-
oratory for INR estimation and dosing decisions,
• or phlebotomy and dosing in practice with INR testing
performed by the laboratory,
• or phlebotomy with INR estimation and dosing deci-
sions being made in the primary care clinic.
This study focused on the practicalities of the PSM model
within the NHS with particular emphasis on training,
cost, and clinical effectiveness. It was important for self-
management of oral anticoagulation to prove that com-
pared to routine management and including all follow up
costs, it is cost effective and gives at least equally good
clinical outcomes. Monitoring costs and the cost of treat-
ing thromboembolic and haemorrhagic complications
were therefore compared.
Hypothesis
There is no difference in therapeutic control of patients
self managing their oral anticoagulation therapy in com-
parison with standard care in patients on long term oral
anticoagulation therapy.
Aim
To determine the clinical and cost effectiveness of patient
self-management (PSM) in comparison with standard
care in patients on long term oral anticoagulation therapy.
Objectives
 To assess whether patients (or a carer) manage their
own anticoagulation therapeutic control in terms of per-
centage of time spent within therapeutic range, as effec-
tively as patients receiving standard care.
 To investigate the cost effectiveness of PSM with regard
to monitoring costs (with cost-modelling for the treat-
ment of serious adverse events, particularly stroke).
 To provide information on the types of patient who
may potentially benefit or who may be unsuitable for this
model of care.
 To determine patient preferences and utilities with
regard to patient self-management.
Method
The study was a multi-centred randomised controlled
trial. Patients on long term warfarin therapy from 48 gen-
eral practices within the West Midlands and surrounding
areas were recruited with support from the Midlands
Research Consortium (MiDReC). Practices were selected
to represent a geographic spread of rural/suburban centres
and to cover a wide socio-economic range of patients.
(Figure 1).
Patient recruitment
Patients' suitable for trial inclusion were identified from a
practice-generated computer list. The inclusion criteria
was patients aged 18 or over, with a long term (greater
than 12 months) indication for oral anticoagulation, who
had taken warfarin for at least six months and were willing
(or in the case of dependent patients both they and theirPage 3 of 7
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defined as someone who takes care of the patient, but is
not employed to do so, e.g., partner, spouse, other
relative.
Exclusion criteria for the trial was patients with a short-
term indication (less than 12-months) for warfarin ther-
apy:aged under 18 years of age; resident in a nursing
home; or physically unable to attend the surgery. Patients
who had moved out of the area, become terminally ill,
discontinued warfarin or died were also excluded.
There were are no other absolute exclusion criteria, but
patients were only invited to enter into the study if both
the research team and the patients own GP agreed that
there was uncertainty as to which model of care would
provide the best therapeutic control. Thus, if a GP felt that
a patient would be unable to cope with PSM, the patient
was not invited to enter into the study.
All remaining patients were sent letters from their GP
inviting them to participate in the study; together with
information sheets, reply slips and free post envelopes.
They were asked to complete the reply slip regardless of
whether they wished to participate as it informed on edu-
cation and ethnicity and the reason why they did not wish
to take part. A follow up letter was sent if no response was
received after 2 weeks.
This method of selection was as inclusive as possible and
allowed no room for subjectivity based on previous con-
trol or compliance.
Summary of study designFigure 1
Summary of study design
Study completion
data collection
QOL and interviews
3 month assessment clinic
data collection
3 month assessment clinic
data collection
3 month assessment clinic
data collection
PSM training
20% drop out
264 patients
Baseline questionnaires
330 pts
PSM
Retrospective data collection
study completion
data collection
QOL and interviews
3 month data collection
3 month data collection
3 month data collection
330 pts
Control
Retrospective data collection
1320 patients invited to
discuss trial
50% eligible = 660
44 patients per practice
6 /1000 on warfarin
1320 patients
30 practices = 220,000 ptsPage 4 of 7
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Primary outcome measure
Therapeutic INR control in terms of percentage of time
spent within therapeutic range. Percentage time in range
was calculated according to Rosendaal's equation [27]
which assumes a linear change between INR results
through a specific software programme (BAP-PC, Bir-
mingham University).
Secondary outcome measure
Major bleeding and thrombotic complications and associ-
ated deaths
Cost- effectiveness
Patient satisfaction and attitudes to self management.
Information sessions
Patients giving a positive response to the invitation letter
were asked to attend an information session at their prac-
tice to explain the purpose of the study, potential advan-
tages (personal and societal); and the implications of
taking part.
Patients willing to participate who gave written informed
consent were randomly allocated to either PSM or control.
Patient training
Patients randomised to the intervention arm (i.e. PSM)
attended at least two training sessions, with the option of
a third session. The training sessions were based on those
used in Germany [28] but were less formal and intensive.
A number of trained anticoagulation nurses were
employed to help with patient training. The training ses-
sions were practice-based, held for a maximum of 6
patients at a time (limited to 4 if possible) held 1 week
apart.
Each patient was individually assessed to satisfy the
research team that they were capable of undertaking PSM.
A certificate was given to each patient to certify that they
had successfully completed the training course. For those
patients who did not meet the assessment criteria, an
additional session was arranged. Patients then not consid-
ered capable of PSM were asked to return to their usual
care and followed-up within the PSM arm, with the reason
for withdrawal documented. Identical data for withdrawn
patients were monitored as for the control patients for the
period of the trial intervention. The NPT device used in
this study was the 'Coaguchek S' (Roche Diagnostics).
Trial procedure
The intervention patients managed their own anticoagula-
tion for a period of 12 months. Throughout the trial the
patient performed their INR test once every 2 weeks,
unless a dosage change was made then they performed the
test after 1 week. Senior research personnel were available
for support and advice as necessary via a pager.
Intervention patients were asked to attend a practice-
based clinic every 3 months for assessment of their
progress and to perform quality control procedures. These
clinics were managed by research personnel and involved
enquiries regarding general health and haemorrhagic or
thrombotic complications. If at the 3-month assessment
any patient was deemed not to be managing self-manage-
ment effectively they were asked to undertake further
training. If they were still not competent in self-manage-
ment following further training they were required to
withdraw from the study.
Data were collected from all participating hospital labora-
tories and practice based clinics regarding the technique
and reagents used for measuring INR. Baseline INR and
demographic data were collected retrospectively for 6
months on all patients at study entry. Intervention (PSM)
patients recorded INR results and warfarin dose on a case
report form.
Control patients continued with their pre-study care
either attending hospital or practice based anticoagulant
clinics. Research personnel collected control and excluded
patients' INR results and warfarin dose from the responsi-
ble anticoagulation clinic (hospital or practice). At six
monthly intervals and at the end of the study GP records
of PSM, control and excluded patients were reviewed for
any mention of hospital admission, to ascertain any
adverse events including fatalities, and whether they were
still taking warfarin. If a major haemorrhagic or throm-
botic event was identified patients were withdrawn from
the study.
Data on any complications related to oral anticoagulation
therapy for patients in the control arm of the study were
collected from patient records held at the general practice.
Control patients were not asked to self report adverse
events. Data on adverse events for patients in the interven-
tion arm were collected from the GP records and patients
were asked to self report events by completing an adverse
events clinical report form.
Patients names were flagged at the central register by NHS
number, to facilitate collection of mortality data. Postal
questionnaires were sent to study participants at baseline,
six months and 12 months. A random sample of patients
in both the PSM and control groups were also asked to
complete a cost questionnaire and invited to participate in
focus groups to inform conjoint analysis centred around
willingness to pay for this model of care. Standardised,
validated and reliable measures were used for collectingPage 5 of 7
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well-being. The use of the SF-12 allowed the measurement
of changes in broad aspects of health status. Similarly the
use of EQ-5D allowed the measurement of broad aspects
of quality of life.[29,30] The EQ-5D not only allowed
changes in health status to be measured but also valued,
using the University of York Measurement and Valuation
of Health general population survey tariff.[31]
The cost analysis adopted a broad perspective to include
costs incurred within the health sector and by patients and
carers. Data collection was undertaken on all trial patients
in order to allow a stochastic cost analysis to be
conducted. The focus of the data collection was upon the
key cost drivers which included; anticoagulation clinic
attendances in primary and secondary care, contact with
GPs; contact with secondary care, both outpatient and
inpatient; consumables used in treatment provision and
drugs. The analysis adopted an incremental approach
such that data collection was concentrated on resource use
differences between trial arms.
Unit costs were collected from published sources and a
representative sample of NHS providers in order to
increase generalisability. The methods used to collect data
included patient questionnaires and a review of patient
records (both GP and hospital). Data on private costs was
collected from a survey of a sub-cohort of the trial
population.
Statistical analysis
For the primary outcome that INR control, in terms of per-
centage of time spent in range in both groups to be equiv-
alent at a level of 10%, with 5% significance and 80%
power, 261 patients were needed in each group (total
522). This was also sufficient for the secondary outcomes
for patient satisfaction on either EQ-5D or SF-12. These
patients numbers provided sufficient power to show a
four point difference in the two groups with a significance
of 5% at 80% power. These numbers were also able to
detect a 13% change in those reporting a problem with
pain and discomfort on the EQ-5D and a five point
increase in mean score on the visual analogue scale, at the
same power and significance. This sample size also
allowed the detection of a drop from 4 events per hundred
patient years to 0.2 events per hundred patient years at the
same power and significance. Because of an estimated
20% drop-out rate from the PSM arm, the study proposed
to recruit 660 patients.
The types of analysis proposed were Chi-square, log-linear
models, logistic regression and survival analysis, t-tests,
ANOVA and non-parametric equivalents.
The t-tests or a non-parametric equivalent was used to
examine the differences between the two main groups for
the percentage of time spent within therapeutic range and
ANOVA or its non-parametric equivalent for detecting
changes in time spent within range for more than 2 target
therapeutic groups. Chi-squared and log-linear models
were used to examine demographic data. Logistic
regression was used to search for predictors of adverse
events. Survival analysis was used to see whether there is a
difference in time to the 1st adverse event (assuming there
are sufficient events).
Discussion
This is an important study in terms of developing an evi-
dence base for the utility of patient self-management of
oral anticoagulation in the UK. Previous studies have used
highly selected populations in observational non-ran-
domised trials.
This study aimed to recruit all patients aged 18 and over
who take oral anticoagulant therapy, although a small
proportion of patients were excluded by practice staff or
GPs for reasons of co-morbidity or immobility.
The principle contentious issue within this methodology
was the role of training. It could be argued that all patients
should be trained and that randomization should only
occur once patients have been trained. In this way any
confounding effect produced by training would be
negated. We felt that this process would be unethical and
training patients for a service that they would not receive
seemed inequitable. As training focused primarily on the
ability to perform the INR test accurately, and to interpret
this into a warfarin dose, this should not affect their INR
control. Similarly all patients receiving warfarin should
have received the basic level of education provided when
they first started.
The methodology used in this trial will overcome con-
cerns of selection bias and relevance to the UK health serv-
ice. Based on a pilot study, it was anticipated that 50% of
patients invited to participate would be recruited but, in
fact, there was just 25% response. Also there was a 30%
drop out during or immediately following training
instead of the 20% anticipated. The study will give a
clearer understanding of who might benefit from this
model of care.
Study completion is anticipated for July 2003, with results
available by November 2003.
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